User login
Key clinical point: Allogeneic stem cell transplantation (alloSCT) results in long-term disease control in patients with mantle cell lymphoma (MCL), including those with TP53-mutated disease, and should be considered for earlier use in these high-risk patients who are unresponsive to conventional chemoimmunotherapy.
Major finding: The estimated overall survival rates were 56% (95% CI 36%-72%) at 10 years for the overall cohort and 59% (95% CI 21%-75%) at 4 years for patients with TP53-mutated disease at median follow-ups of 10.8 and 4.2 years, respectively. No relapses were observed in the TP53-mutated subset beyond 6 months after transplantation.
Study details: This retrospective study included 36 patients who underwent alloSCT for MCL, including 13 patients with TP53-mutated disease.
Disclosures: This study did not receive any funding. Some authors declared serving as advisory board members for or receiving honoraria, research funding, or speaker fees from various sources.
Source: Lew TE et al. Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53-mutated disease. Leuk Lymphoma. 2023 (Aug 2). doi: 10.1080/10428194.2023.2241095
Key clinical point: Allogeneic stem cell transplantation (alloSCT) results in long-term disease control in patients with mantle cell lymphoma (MCL), including those with TP53-mutated disease, and should be considered for earlier use in these high-risk patients who are unresponsive to conventional chemoimmunotherapy.
Major finding: The estimated overall survival rates were 56% (95% CI 36%-72%) at 10 years for the overall cohort and 59% (95% CI 21%-75%) at 4 years for patients with TP53-mutated disease at median follow-ups of 10.8 and 4.2 years, respectively. No relapses were observed in the TP53-mutated subset beyond 6 months after transplantation.
Study details: This retrospective study included 36 patients who underwent alloSCT for MCL, including 13 patients with TP53-mutated disease.
Disclosures: This study did not receive any funding. Some authors declared serving as advisory board members for or receiving honoraria, research funding, or speaker fees from various sources.
Source: Lew TE et al. Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53-mutated disease. Leuk Lymphoma. 2023 (Aug 2). doi: 10.1080/10428194.2023.2241095
Key clinical point: Allogeneic stem cell transplantation (alloSCT) results in long-term disease control in patients with mantle cell lymphoma (MCL), including those with TP53-mutated disease, and should be considered for earlier use in these high-risk patients who are unresponsive to conventional chemoimmunotherapy.
Major finding: The estimated overall survival rates were 56% (95% CI 36%-72%) at 10 years for the overall cohort and 59% (95% CI 21%-75%) at 4 years for patients with TP53-mutated disease at median follow-ups of 10.8 and 4.2 years, respectively. No relapses were observed in the TP53-mutated subset beyond 6 months after transplantation.
Study details: This retrospective study included 36 patients who underwent alloSCT for MCL, including 13 patients with TP53-mutated disease.
Disclosures: This study did not receive any funding. Some authors declared serving as advisory board members for or receiving honoraria, research funding, or speaker fees from various sources.
Source: Lew TE et al. Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53-mutated disease. Leuk Lymphoma. 2023 (Aug 2). doi: 10.1080/10428194.2023.2241095